Get the Stockscreener App
103.52
0.08%
0.08
After Hours:
104.55
1.03
+0.99%
Insmed Inc stock is traded at $103.52, with a volume of 1.64M.
It is up +0.08% in the last 24 hours and down -2.25% over the past month.
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
See More
Previous Close:
$103.44
Open:
$104.07
24h Volume:
1.64M
Relative Volume:
0.45
Market Cap:
$18.86B
Revenue:
$381.03M
Net Income/Loss:
$-1.01B
P/E Ratio:
-17.40
EPS:
-5.95
Net Cash Flow:
$-789.25M
1W Performance:
-0.62%
1M Performance:
-2.25%
6M Performance:
+31.91%
1Y Performance:
+39.08%
1-Day Range:
$102.65
$104.95
1-Week Range:
$101.59
$105.01
52-Week Range:
$60.40
$106.83
Insmed Inc Stock (INSM) Company Profile
Name
Insmed Inc
Sector
Industry
Phone
908-977-9900
Address
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
103.52 | 19.65B | 381.03M | -1.01B | -789.25M | -5.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-13-25 | Initiated | Jefferies | Buy |
| Feb-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Apr-23-24 | Initiated | Truist | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Jul-26-23 | Initiated | Guggenheim | Buy |
| Dec-09-22 | Initiated | Mizuho | Buy |
| Dec-07-22 | Initiated | Barclays | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Buy |
| Apr-27-22 | Initiated | Goldman | Buy |
| Dec-06-21 | Initiated | JP Morgan | Overweight |
| Oct-19-21 | Resumed | Monness Crespi & Hardt | Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Oct-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Oct-12-20 | Resumed | Stifel | Buy |
| Sep-03-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-15-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jan-17-19 | Upgrade | Goldman | Neutral → Buy |
| Jan-02-19 | Initiated | Canaccord Genuity | Buy |
| Aug-06-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jul-23-18 | Initiated | Goldman | Neutral |
| Apr-23-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Mar-21-18 | Initiated | Morgan Stanley | Overweight |
| Jan-18-18 | Initiated | Credit Suisse | Neutral |
| Sep-05-17 | Reiterated | Evercore ISI | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Robert W. Baird | Outperform |
| Mar-15-16 | Initiated | Stifel | Buy |
| Nov-09-15 | Downgrade | UBS | Buy → Neutral |
| Oct-06-15 | Reiterated | H.C. Wainwright | Buy |
| Jun-09-15 | Initiated | Citigroup | Neutral |
| Mar-26-14 | Reiterated | HC Wainwright | Buy |
View All
Insmed Inc Stock (INSM) Latest News
Is Insmed Incorporated stock a growth or value playFree High-Return Strategy Alerts - jammulinksnews.com
Insmed to Host Second-Quarter 2025 Financial Results Conference Call on Thursday, August 7, 2025 - Lelezard
Insmed’s Rare-Disease Pipeline Draws Investor Interest Ahead Of Key Decisions - Finimize
What drives Insmed Incorporated stock priceAccelerated wealth building - Autocar Professional
Is Insmed Incorporated a good long term investmentHigh-yield growth strategies - Autocar Professional
Insmed Incorporated Stock Analysis and ForecastConsistently superior profits - Autocar Professional
What analysts say about Insmed Incorporated stockRemarkable growth - jammulinksnews.com
Insmed's Price Target Raised to $130 by Wells Fargo - AInvest
Is Insmed Incorporated stock overhyped or has real potentialSafer Investing With Bigger Upside - beatles.ru
Insmed's Trading Volume Drops 46% to $208 Million Ranking 490th in Market - AInvest
Insmed (INSM) Target Price Raised by Morgan Stanley | INSM Stock News - GuruFocus
Insmed price target raised to $108 from $102 at Morgan Stanley - TipRanks
Insmed (INSM) Price Target Raised to $108 by Morgan Stanley | IN - GuruFocus
What makes Insmed Incorporated stock price move sharplyFree Capital Allocation Plans - beatles.ru
Insmed chief legal officer Smith sells $167,755 in stock By Investing.com - Investing.com Canada
Insmed chair and CEO Lewis sells $699k in shares By Investing.com - Investing.com Canada
Jim Cramer Calls Insmed "Very Speculative" - Yahoo Finance
Exploring 3 High Growth Tech Stocks In The US Market - simplywall.st
$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today - Benzinga
Insmed Surges to 292nd in Trading Volume with $31.9 Million Turnover - AInvest
Cramer Says Tesla Dominates While Ouster Is 'Too Speculative' - Benzinga
Insmed(INSM.US) Officer Sells US$5.54 Million in Common Stock - 富途牛牛
JPMorgan Elevates Insmed (INSM) Target Price Amid Positive Outlo - GuruFocus
A Glimpse Into The Expert Outlook On Insmed Through 12 Analysts - Nasdaq
RBC Capital Keeps Their Buy Rating on Insmed (INSM) - The Globe and Mail
United Therapeutics Faces Key Moment With Tyvaso's Q3 Results - Finimize
Insmed Incorporated(NasdaqGS: INSM) added to Russell Small Cap Comp Value Index - MarketScreener
Insmed Incorporated: Riding the Russell Reconstitution Wave in Small-Cap Biotech - AInvest
Insmed Surges to 134th in Trading Volume with $612 Million Day Despite Stock Decline - AInvest
Here’s how Insmed grows to be the next $100 billion biotech - statnews.com
Insmed's Insider Sell-Off: Strategic Exit or Buying Opportunity Ahead of Breakthrough Data? - AInvest
Pulmonary Arterial Hypertension Market Set to Grow Substantially Through 2034, DelveInsight Projects | Merck, Janssen Pharma, Aerovate Therapeutics, Novartis, Insmed Inc, Chugai Pharma, Keros - Barchart.com
Russell Rebalance: 3 Stocks Ready to Move Higher - MarketBeat
Insider Sell: Roger Adsett Sells 10,686 Shares of Insmed Inc (INSM) - GuruFocus
Mizuho Reiterates Outperform Rating on Insmed (INSM), Boosts PT to $110 - Insider Monkey
10 Best Growth Stocks to Buy According to Billionaires - Insider Monkey
Wells Fargo Lifts Price Target on Insmed Incorporated (INSM) to $119 From $107 - Insider Monkey
Insmed Trading Volume Plummets 51.8% to $217 Million Ranking 354th in Market Activity - AInvest
Is Insmed Stock Overvalued at $98? - Nasdaq
Goldman Sachs Hikes Insmed (INSM) Price Target to $112 Affirms Buy Rating - Insider Monkey
Insmed Completes $750 Million Follow-On Public Offering - Global Legal Chronicle
Is Insmed Stock Overvalued After The 45% Jump? - Forbes
Insmed Inc Stock (INSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.57%
1.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):